ARWR

Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?

Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications

Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright

Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models